Singular Genomics Systems Inc is a medical instruments & supplies business based in the US. Singular Genomics Systems shares (OMIC) are listed on the NASDAQ and all prices are listed in US Dollars. Singular Genomics Systems employs 238 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $4.02 |
|---|---|
| 52-week range | $2.66 - $27.57 |
| 50-day moving average | $3.50 |
| 200-day moving average | $8.43 |
| Wall St. target price | $10.17 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.57 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.02 from 2022-07-01
| 1 week (2022-06-27) | 6.63% |
|---|---|
| 1 month (2022-06-03) | 20.36% |
| 3 months (2022-04-04) | -37.58% |
| 6 months (2022-01-04) | -63.02% |
| 1 year (2021-07-02) | -85.45% |
|---|---|
| 2 years (2020-06-30) | N/A |
| 3 years (2019-06-30) | N/A |
| 5 years (2017-06-30) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -18.34% |
| Return on equity TTM | -61.83% |
| Profit margin | 0% |
| Book value | $4.50 |
| Market capitalisation | $283.8 million |
TTM: trailing 12 months
We're not expecting Singular Genomics Systems to pay a dividend over the next 12 months.
Singular Genomics Systems, Inc. , a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.